Sarcoidosis Drugs Market: By Product Type Inhibitors, Corticosteroids, Immunosuppressant Drugs, Others), By Route of Administration, By Distribution Channel, and Geography  

Sarcoidosis Drugs Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Tumor Necrosis Factor Alpha (TNF-?) Inhibitors, Corticosteroids, Immunosuppressant Drugs, Others), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region  

Sarcoidosis Drugs Market was valued at US$ 267.9 million in 2022 and is anticipated to grow at a CAGR of 5.3% over 2023-2029. The sarcoidosis drug market is the pharmaceutical market dedicated to the development and commercialization of sarcoidosis medications.  Sarcoidosis is a chronic inflammatory illness that affects a variety of organs, most notably the lungs and lymph nodes. It is distinguished by the growth of tiny inflammatory nodules known as granulomas. While the specific etiology of sarcoidosis is uncertain, an aberrant immune response is thought to be involved. There is no cure for sarcoidosis at the moment, however, the sarcoidosis medicine market provides a variety of treatment choices, including corticosteroids, immunosuppressive agents, and biologics. The primary purpose of these treatment options is to reduce inflammation, regulate symptoms, and prevent organ damage. The most important factor driving the growth of the sarcoidosis medicine market is the increasing prevalence of sarcoidosis worldwide.

According to the American Lung Association, almost 200,000 instances of sarcoidosis are recorded each year in the United States. Furthermore, advances in medical research and knowledge of the underlying processes of sarcoidosis are helping to create targeted therapeutics. The growing emphasis on personalized therapy and the development of medications that target particular pathways or molecular targets linked with sarcoidosis also have an impact on the sarcoidosis drug market. Ongoing research and development efforts, along with collaborations between pharmaceutical companies, healthcare providers, and regulatory authorities are creating significant opportunities for the development of the sarcoidosis drug market.

However, high cost and time-consuming factors associated with developing novel drug molecules and lack of awareness of sarcoidosis among the general public and some healthcare professionals create challenges for the development of treatment options for sarcoidosis. Various pharmaceutical companies are constantly doing research and engaged in expanding innovative therapeutic options to treat sarcoidosis. For instance, in June 2023, Molecure submitted an investigational new drug (IND) application with the US Food and Drug Administration (FDA) before beginning a Phase II study in pulmonary sarcoidosis with its Chitotriosidase (CHIT1) inhibitor (OATD-01).

Sarcoidosis Drugs Market Key Developments:   
  • In November 2022, Kinevant Sciences reported that the first patient has been dosed in Phase 2 Study of Namilumab for the Treatment of Pulmonary Sarcoidosis (RESOLVE-Lung).
  • In January 2023, aTyr Pharma Inc. announced that the European Commission (EC) granted orphan drug designation efzofitimod, which is currently in Phase 3 study for the treatment of sarcoidosis based on the opinion of the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP).

Global Sarcoidosis Drugs Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

5.3%

Largest Market

North America

Fastest Growing Market

North America

Sarcoidosis Drugs Market Dynamics

Increase in the prevalence of sarcoidosis due to bacterial and viral infections drives the global sarcoidosis drug market. Moreover, raise in funding by public and private sectors for the development of newer drugs, technological advancements for the disease diagnosis, strong product pipeline for the sarcoidosis treatment, and increase in healthcare expenditure are surge global sarcoidosis drugs market over the forecast years. However, stringent regulations for product approval, adverse effects associated with the drugs, and poor disease awareness in underdeveloped countries are impede the growth of the global sarcoidosis drug market.

Global Sarcoidosis Drugs Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2022

US$ 267.9 million

Market CAGR

5.3%

By Drug Class

  • Tumor Necrosis Factor Alpha (TNF-?) Inhibitors
  • Corticosteroids
  • Immunosuppressant Drugs
  • Others

By Route-Administration

  • Oral
  • Parenteral
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup's details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis

Download Free Sample Report

Frequently Asked Questions

The sarcoidosis drugs market is projected to expand at a CAGR of 5.3% during the forecast period.

Novartis AG (Switzerland), Merck & Co., Inc., (U.S.), Advenchen Laboratories, LLC (U.S.), EpiZyme, Inc. (U.S.), Araim Pharmaceuticals, Inc. (U.S.), Relief Therapeutics Holding SA (Switzerland)

North America is the fastest-growing region for the sarcoidosis drug market

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Sarcoidosis Drugs Market Introduction 
2.1.Global Sarcoidosis Drugs Market  - Taxonomy
2.2.Global Sarcoidosis Drugs Market  - Definitions
2.2.1. By Drug Class
2.2.2. By Route-Administration
2.2.3. By Distribution Channel
2.2.4. By Region
3.Global Sarcoidosis Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Sarcoidosis Drugs Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Sarcoidosis Drugs Market  By Drug Class, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. Tumor Necrosis Factor Alpha (TNF-?) Inhibitors
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Corticosteroids
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Immunosuppressant Drugs
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Others
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Sarcoidosis Drugs Market  By Route-Administration, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Oral
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Parenteral
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Others
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7.Global Sarcoidosis Drugs Market  By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online Pharmacies
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Sarcoidosis Drugs Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Sarcoidosis Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Tumor Necrosis Factor Alpha (TNF-?) Inhibitors
9.1.2.Corticosteroids
9.1.3.Immunosuppressant Drugs
9.1.4.Others
9.2.  Route-Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Oral
9.2.2.Parenteral
9.2.3.Others
9.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Online Pharmacies
9.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Sarcoidosis Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Tumor Necrosis Factor Alpha (TNF-?) Inhibitors
10.1.2.Corticosteroids
10.1.3.Immunosuppressant Drugs
10.1.4.Others
10.2.  Route-Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Oral
10.2.2.Parenteral
10.2.3.Others
10.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Online Pharmacies
10.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Sarcoidosis Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Tumor Necrosis Factor Alpha (TNF-?) Inhibitors
11.1.2.Corticosteroids
11.1.3.Immunosuppressant Drugs
11.1.4.Others
11.2.  Route-Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Oral
11.2.2.Parenteral
11.2.3.Others
11.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Online Pharmacies
11.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Sarcoidosis Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Tumor Necrosis Factor Alpha (TNF-?) Inhibitors
12.1.2.Corticosteroids
12.1.3.Immunosuppressant Drugs
12.1.4.Others
12.2.  Route-Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Oral
12.2.2.Parenteral
12.2.3.Others
12.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Online Pharmacies
12.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Sarcoidosis Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Tumor Necrosis Factor Alpha (TNF-?) Inhibitors
13.1.2.Corticosteroids
13.1.3.Immunosuppressant Drugs
13.1.4.Others
13.2.  Route-Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Oral
13.2.2.Parenteral
13.2.3.Others
13.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Online Pharmacies
13.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Novartis AG (Switzerland)
14.2.2.Merck & Co., Inc., (U.S)
14.2.3.Advenchen Laboratories, LLC (U.S)
14.2.4.EpiZyme, Inc. (U.S.)
14.2.5.Araim Pharmaceuticals, Inc. (U.S.)
14.2.6.Relief Therapeutics Holding SA (Switzerland)
14.2.7.Adaptimmune Therapeutics (U.K.)
14.2.8.Bellus Health, Inc. (Canada)
14.2.9.Firststring Research, Inc. (U.S.)
14.2.10.PharmaIN Corporation (U.S.)
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • Novartis AG (Switzerland)
  • Merck & Co., Inc., (U.S)
  • Advenchen Laboratories, LLC (U.S)
  • EpiZyme, Inc. (U.S.)
  • Araim Pharmaceuticals, Inc. (U.S.)
  • Relief Therapeutics Holding SA (Switzerland)
  • Adaptimmune Therapeutics (U.K.)
  • Bellus Health, Inc. (Canada)
  • Firststring Research, Inc. (U.S.)
  • PharmaIN Corporation (U.S.)

Related Industry Reports